Browsing Tag
Retatrutide
3 posts
Lilly selects Lehigh Valley, Pennsylvania for obesity drug manufacturing plant
Lilly is building a $3.5B injectable medicine facility in Pennsylvania to scale retatrutide. Find out how this reshapes the obesity drug market and U.S. supply.
What’s next after Zepbound? Inside Eli Lilly and Company’s pipeline beyond GLP-1
Discover which drugs Eli Lilly and Company is betting on after Zepbound, including oral GLP-1 pills and next-generation incretins that could redefine the global obesity treatment market.
Can high-dose GLP-1 therapies reshape obesity care—or are we nearing the biological ceiling?
Are high-dose GLP-1 drugs like Wegovy 7.2mg and Zepbound 15mg unlocking better weight loss—or just more side effects? Here’s what the latest data suggests.